Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies

21 Nov 2018

• By Joseph Haas, Jo Shorthouse, John Davis, and Eleanor Malone

BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.

Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies

More from Deals

More from Business